The AI-based adaptive radiation treatment is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot
HCG Cancer Hospital, Bengaluru has launched India’s first Varian Ethos therapy, an Artificial Intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. The new solution is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot. It uses augmented intelligence, a convergence of people and artificial intelligence (AI) working together for better outcomes. This game-changing radiation therapy personalises cancer care using Adaptive Intelligence based on the patient’s anatomy and the position of the tumour at the time of treatment.
Ethos Therapy, the first-of-its-kind in India and a novel technique in the world provides the ability to alter the treatment plan based on tumour and anatomical changes. This unique technology can capture movements in internal or external anatomy during each treatment and enhance their pre-treatment plans by enabling them to gain insight through the advanced power of AI-enhanced image segmentation and treatment planning. It also applies automated dose accumulation to forecast and monitor treatment progress and enhances the treatment ability by making radiation personalised and targeted that gives better outcomes with minimised side effects. The system enables clinicians to efficiently deliver an entire personalised treatment in a 15-minute timeslot which is significantly shorter compared with other treatment systems that take more than 40 minutes, often due to the manual reconfiguration of the treatment.
Dr BS Ajaikumar, Executive Chairman, HealthCare Global Enterprises, said, “We are happy to unveil the pathbreaking Ethos therapy, a key milestone in HCG’s pioneering strides towards precision and personalised cancer care. Adaptive therapy is indeed the future of radiation therapy, and Ethos bears testimony to our ceaseless commitment to improve cancer treatment and enhance patient outcomes through the adoption of cutting-edge technology”.
Raj Gore, CEO, HealthCare Global Enterprises said, “We are delighted to introduce the highly innovative Ethos therapy in India by of our partnership with Varian. A pioneer in targeted cancer treatments, HCG has always lived up to its promise of “adding years to life”. We remain unflinchingly committed to reducing the global cancer burden through a judicious blend of advanced technology and the depth of domain knowledge, experience, and expertise.”